Recent Developments in Immuno-oncology: Biomarkers, Pan-tumor Studies, Novel Treatment Combinations, and the Management of Adverse Events

View Activity

FACULTY

Arjun V. Balar, MD
Assistant Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY

PROGRAM OVERVIEW

This whiteboard preceptorship will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses, and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Review potential predictive or prognostic immune-related biomarkers and biomarker testing methodologies
  • Examine clinical evidence supporting the use of immune checkpoint inhibitors both as monotherapy and combination with chemotherapy or other immune agents.
  • Recognize and manage immune-related adverse events (irAEs) associated with the use of checkpoint inhibitors
  • Explain patient-centered shared decision-making approaches aimed at optimizing cancer care and survivorship and the roles of the multidisciplinary team members in diagnosing and managing irAEs

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients who are treated or eligible for treatment with immunotherapy.
CNE Credits: 1.0 ANCC Contact Hour.

ONCC Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

PHARMACISTS

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Successful completion of this program qualifies for up to 1.0 knowledge-based contact hour for pharmacists.
Event UAN(s): JA4008163-9999-20-048-H04-P, JA4008163-9999-20-048-H04-T
Note: The only official Statement of Credit is the one you pull from CPE Monitor.
Amedco LLC certifies that the attendee named above has participated in the enduring activity titled IC-ONC: Enduring Whiteboard online between 4/13/2020 and 4/13/2021 and is awarded the number of credit hours listed above.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY

Arjun Balar, MD, has received consultant fees from Merck, Genentech, AstraZeneca, Pfizer, and Seattle Genetics; and received fees for non-CME/CE services received directly from a commercial interest or its agent from Merck, Genentech, and AstraZeneca.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services, has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: April 13, 2020

EXPIRATION DATE: April 13, 2021

ENDURING MATERIAL LEARNER NOTIFICATION

IC-ONC: Enduring irAE track – Recent Developments in Immuno-oncology: Management of Adverse Events
Date of CE Release: April 13, 2020
Date of CE Expiration: April 13, 2021
Location: Online

Acknowledgement of Financial Commercial Support

Bristol-Myers Squibb, Merck & Co., Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.
If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Pharmacists

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1.0 knowledge-based contact hours for pharmacists/technicians. Learners should claim only the credit commensurate with the extent of their participation in the activity.
UAN(s): JA4008163-9999-20-048-H04-P, JA4008163-9999-20-048-H04-T

NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

Objectives – After attending this program you should be able to:
1. Examine clinical evidence supporting the use of immune checkpoint inhibitors both as monotherapy and combination with chemotherapy or other immune agents.
2. Review potential predictive or prognostic immune-related biomarkers and biomarker testing methodologies.
3. Recognize and manage immune-related adverse events (irAEs) associated with the use of checkpoint inhibitors.
4. Explain patient-centered shared decision-making approaches aimed at optimizing cancer care and survivorship and the roles of the multidisciplinary team members in diagnosing and managing irAEs.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco, LLC. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name Relationship : Commercial Interest
Ana Maria Albino NA
Dr. Balar Consultant: Merck, Genentech, AstraZeneca, Pfizer, and Seattle Genetics; Fees from Non-CME Services: Merck, Genentech, and AstraZeneca
Matthew Frese NA
Christina Gallo NA
Brianna Hanson NA
Nicole Longo NA
Scott McGee-Plys NA

View Activity

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.